Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153198 | 0.87 | SCN8A (0.49) | SCN8AKDM4EALDH1A1HTTTDP1 | |
| SCHEMBL16269252 | 0.85 | ALDH1A1 (0.48) | SCN8AKDM4EALDH1A1HTTTDP1 | |
| SCHEMBL13436118 | 0.80 | SCN8A (0.54) | SCN8AKDM4EALDH1A1HTTTDP1 | |
| SCHEMBL13995846 | 0.78 | MPO (0.46) | SCN8AKDM4EALDH1A1HTTSLC6A4 | |
| SCHEMBL13995700 | 0.78 | MPO (0.46) | SCN8AKDM4EALDH1A1HTTSLC6A4 | |
| SCHEMBL12153073 | 0.78 | SCN8A (0.52) | SCN8AKDM4EALDH1A1HTTTDP1 | |
| SCHEMBL16269210 | 0.77 | GAA (0.50) | SCN8AKDM4EALDH1A1HTTTDP1 | |
| SCHEMBL16268467 | 0.77 | SCN8A (0.53) | SCN8AKDM4EALDH1A1HTTTDP1 | |
| SCHEMBL16269169 | 0.77 | SCN8A (0.44) | SCN8AKDM4EALDH1A1HTTTDP1 | |
| SCHEMBL13995914 | 0.77 | MEN1 (0.46) | ALDH1A1EPHX2PPARGTACR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | SCN8A 1482/4885KDM4E 1846/4885ALDH1A1 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.